Heron Therapeutics, Inc. - HRTX Aggregate Business Value
Heron Therapeutics is expanding its portfolio of hospital products and non-opioid anesthetics to reduce reliance on cancer supportive care treatments. Heron Therapeutics is building relationships with distributors and clinic networks to implement its medical programs. This price action on the GURU.Markets platform shows an Enterprise Value of 159.46, while the business relies on specialized delivery of analgesic drugs.
Summary analytical data breakdowns for Heron Therapeutics, Inc. (HRTX)
Enterprise Value (EV) combines market capitalization and net debt, reflecting the total cost of acquiring all business assets and liabilities. By analyzing the real market price of Heron Therapeutics (HRTX) on GURU.Markets, an investor assesses the justification of the valuation through the lens of exclusive patents for ZYNRELEF and stringent FDA requirements, which create high barriers to entry for competitors.